PM1009
Phase 2Small molecule
PM1009 is one of 12 small molecule programs targeting First-line. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in First-Line
#DrugCompanyPhaseTrials
1COLUMVI
RochePhase 2
Polivy
RochePhase 2
Brukinsa
BBeOne Medicines
Phase 2
AAA617
NovartisPhase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Targeted Therapy
FFudan University
Phase 2
PM8002
BBiotheus Inc.
Phase 2
Delstrigo
PProfessor Francois Venter
Phase 3
EGFR-TK Inhibitor
LLuBing
Phase 2
PM1009
BBiotheus Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PM1009. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBiotheus Inc.